Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 REJOICE-Ovarian trial of raludotatug deruxtecan maintenance with or without bevacizumab versus standard maintenance in newly diagnosed advanced non-HRD-positive ovarian cancer
MOH_2026-07-22_016949Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raludotatug deruxtecan and bevacizumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
raludotatug deruxtecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2026-07-22_016949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-22_016949.